【摘要】 目的：对新型调节血脂药前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂进行评价，为医疗机构遴选药品提供依据。方法：依据《中国医疗机构药品评价与遴选快速指南(第二版)》,从药学特性、有效性、安全性、经济性、其他属性5大维度，对依洛尤单抗、阿利西尤单抗、托莱西单抗和英克司兰等4种PCSK9抑制剂进行评分，并根据药品评分结果给出推荐意见。结果：依洛尤单抗、阿利西尤单抗、托莱西单抗和英克司兰的评分分别为81.3、73.4、70.3和76.9分。上述4种PCSK9抑制剂均强推荐进入医疗机构采购目录或保留使用。结论：4种PCSK9抑制剂在不同属性中各有优势，实际应用中可依据临床情况及患者需要选择更为适宜的药品。更多还原

【Abstract】 OBJECTIVE: To evaluate the new lipid-regulating drugs proprotein convertase subtilisin/kexin type 9(PCSK9) inhibitors, and to provide basis for drug selection in medical institutions. METHODS: According to A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition), 4 kinds of PCSK9 inhibitors evolocumab, alirocumab, tafolecimab, and inclisiran were evaluated from five dimensions of pharmaceutical characteristics, efficacy, safety, economy, and other attributes. And based on the drug evaluation results, recommendations were provided. RESULTS: The scores for evolocumab, alirocumab, tafolecimab, and inclisiran were respectively 81.3, 73.4, 70.3 and 76.9. The 4 kinds of PCSK9 inhibitors were strongly recommended for inclusion in the health care procurement catalogue or for retention. CONCLUSIONS: The 4 kinds of PCSK9 inhibitors have their own advantages in different attributes. In practical application, drugs can be selected appropriately according to clinical conditions and patients’ needs.更多还原